Brief: Canbridge Pharmaceuticals Posts FY Revenue RMB31.2 Mln
22/03/2022 23:04
March 23 (Reuters) - Canbridge Pharmaceuticals Inc
1228.HK :
* LOSS FOR YEAR INCREASED BY ABOUT RMB231.0 MILLION FROM
RMB846.0
MILLION FOR YEAR
* LOSS FOR YEAR RMB1,077.0 MILLION
* FY REVENUE RMB31.2 MILLION VERSUS RMB12.0 MILLION
Source text for Eikon: ID:
Further company coverage: 1228.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares